Grifols Escrow Issuer S.A. EO-Notes 2021(21/28) Reg.S
- BID
99.103
- ASK
99.906
- 550,000 Nom.550,000 Nom.
- 07/28, 13:05:33 PM
Type of financial instrument
Corporate Bond
Sub-Type
Technology
Yield
4.35
Yield spread Bundesanleihe
1.5690
Tradable for private investors
No
Minimum amount tradeable unit
100,000.00
Maturity
15/10/2028
Interest Rate
3.875 %
Currency
Euro
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE / YIELD | 99.103 G / 4.35 | 0 Units |
| PRICE DETERMINATION TIME | 07/28/2026 / 01:05:33 PM | |
| DAILY VOLUME (NOMINAL) | 0 | |
| YIELD SPREAD | 1.5690 | |
| FIXINGPRICE | - | |
| DAILY HIGH / LOW | 99.103 | 98.24 |
| PREV. DAY'S PRICE | 99.098 | (07/27) |
| CHANGE DAY BEFORE | +0.00 | 0.01 % |
| 52 WEEK HIGH / LOW | 99.27 (02/27) | 95.519 (07/25) |
Master Data
| WKN | A3KW11 |
| ISIN | XS2393001891 |
| SYMBOL | - |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Corporate Bond |
| SUB-TYPE | Technology |
| ISSUER | Grifols S.A. |
| S&P RATING | Please log in to view this field |
| (TRADING) SEGMENT / TICKS | -/ - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| INTEREST RATE | 3.875 % |
| INTEREST RUN FROM | 05/10/2021 |
| NEXT INTEREST PAYMENT | 15/10/2026 |
| UNIT INTEREST FROM NOMINAL AMMOUNT | 1.13 % |
| TRADING CURRENCY / NOTATION | Euro/ Percent |
| NOMINAL CURRENCY | Euro |
| SETTLEMENT CURRENCY | Euro |
| QUOTATION | Continuous trading |
| ISSUING VOLUME | 1.40 Bil. |
| MINIMUM AMOUNT TRADEABLE UNIT | 100,000.00 |
| SMALLEST TRADEABLE UNIT | 1,000.00 |
| MATURITY | 15/10/2028 |
| MARKET MAKER | - |
| STEP UP/ DOWN WHEN RATING CHANGES | No |
| STEP UP FIXED AT ISSUE | No |
| STEP DOWN FIXED AT ISSUE | No |
| BOND CALLABLE BY THE ISSUER | Yes |
| BOND IS SUBORDINATED | No |
Description
Make Whole Call Option.
Tradability Information
Please log in to see the tradability information for this stock.Not registered yet? Create your free account here.
Company profile
Grifols SA is a global specialty plasma therapeutics company that engages in the development, manufacturing, and distribution of a broad range of biological medicines based on plasma-derived proteins. It operates through the following segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma Segment includes all activities related with products deriving from human plasma for therapeutic use. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols i Roig in 1909 and is headquartered in Barcelona, Spain.